FDA recalls several drugs for heart and blood pressure due to possible carcinogen



[ad_1]

SILVER SPRING, Maryland –

The United States Food and Drug Administration alerts health care professionals and patients to the voluntary recall of several drugs containing valsartan, an active ingredient used to treat high blood pressure arterial and heart failure.

This recall is due to an impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products. However, not all products containing valsartan are recalled.

NDMA is clbadified as a probable carcinogen to humans – a substance that can cause cancer – based on laboratory test results. The presence of NDMA is thought to be related to changes in the way the active substance has been manufactured.

"The FDA is committed to maintaining our standard of excellence in safety and effectiveness, including our efforts to ensure the quality of drugs." When we identify failures in the quality of drugs and manufacturing issues that can potentially create risks for patients, we pledge to take prompt action, "said FDA Commissioner Scott Gottlieb, MD."

– Since valsartan is prescribed in drugs for the treatment of serious illnesses, patients taking the recalled valsartan medications should continue to take their medications until they have taken medication.

– To determine if a specific product has been recalled, patients should consult the name of the drug and the name of the company on the label of their prescription b Bottle If the information is not on the bottle, patients should contact the pharmacy that administered the medicine.

– If a patient is taking any of the medications listed below, he must follow the recall instructions provided by the company. This information will be posted on the FDA website

– Patients should also contact their healthcare professional (the pharmacist who prescribed the drug or the doctor who prescribed the drug) if their medication is included in this recall for discuss their treatment, which may include another valsartan product not affected by this recall or other treatment option.

[ad_2]
Source link